RAD BioMed Accelerator

What RAD BioMed Accelerator does

RAD BioMed Accelerator is a Tel Aviv-based early-stage venture accelerator and the dedicated healthcare and deep-technology investment arm of the RAD Bynet Group, one of Israel's most established technology conglomerates with a four-decade legacy spanning 17 enduring companies, 9 IPOs and 10 M&A transactions. The firm co-founded by Yehuda Zisapel, Zohar Zisapel and Prof. Nava Zisapel invests in early-stage Israeli companies developing disruptive medical, health, technology and energy solutions, providing hands-on multidisciplinary support from inception through growth and exit. Its active portfolio comprises 14 companies spanning vascular access (Laminate Medical/VasQ, VGS), neurovascular devices (Perflow), cardiac monitoring (Vectorious Medical/V-LAP), stroke AI triage (CVAid Medical), mobility (SoftWheel, REE Automotive), women's health (FEMSelect/EnPlace), ophthalmology (Belkin Vision, Everads Therapy), radiation shielding (Radiaction), micro-endoscopy (Zsquare), osteoarthritis therapeutics (Moebius Medical/MM-II) and synthetic-biology vaccines (Synvaccine).

The accelerator's revenue mechanics operate through equity investments in portfolio companies, with returns realized via trade-sale acquisitions (Vectorious to Edwards Lifesciences, Belkin Vision to Alcon, Perflow to a Chinese PE firm, SteadyMed to United Therapeutics, Simbionix to 3D Systems, EON Surgical to Teleflex) or IPOs (REE Automotive on NASDAQ), supplemented by out-licensing economics such as Moebius Medical's exclusive worldwide deal with Sun Pharmaceutical Industries. Multiple portfolio technologies are licensed exclusively from leading Israeli institutions including Tel Aviv University, Weizmann Institute, Hebrew University, Technion, Hadassah Medical Center and Sheba Medical Center, anchoring a sourcing pipeline that competitors must replicate from scratch. Distribution for portfolio products takes place via regional direct-sales channels, with several CE-marked devices such as VasQ and Perflow's Stream currently commercialized in Europe while selected companies pursue U.S. and Asian regulatory pathways.

In July 2024, RAD BioMed expanded its mandate beyond MedTech through a strategic partnership with Square One Labs to co-build and co-invest in deep-technology companies in the Energy and Physical AI sectors, extending the RAD Bynet Group's company-building methodology into new verticals. The firm maintains a lean operating footprint of 1-10 employees, with executive leadership including President & CEO David Zigdon (also Executive Chairman of Synvaccine), and operates without a public listing, third-party institutional capital, or disclosed management fees or AUM, relying on the parent conglomerate's balance sheet to finance its accelerator activities.

Name

RAD BioMed Accelerator

Legal name

RAD BioMed Accelerator

Website

https://radbiomed.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1–10 employees

Short description

RAD BioMed Accelerator is a Tel Aviv-based early-stage venture accelerator and the healthcare and deep-tech investment arm of Israel's RAD Bynet Group, building and backing Israeli startups in MedTech, biotech, e-mobility, and emerging energy and Physical AI sectors from inception through IPO or strategic exit.

Ownership category

akta.pro rank

Product category

Venture Capital / Startup Accelerator Services

akta.pro primary industry

Corporate Accelerators & Startup Programs (FSANAHAD)

akta.pro secondary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Venture capital accelerator
• Early-stage MedTech investing
• Medical device startups
• Biotechnology investment
• Israel healthcare ventures

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns: Generating returns through equity investments in early-stage healthcare and technology ventures. RAD BioMed builds companies from inception and supports them through growth to successful exit via acquisition or IPO.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

RAD BioMed Accelerator is an Israel-based early-stage venture capital firm and accelerator that invests in and builds MedTech, HealthTech, Deep Tech, and Energy startups from inception through to successful exit. As the dedicated investment arm of the RAD Bynet Group, it provides founding teams with equity funding, hands-on operational and strategic support, regulatory guidance, and access to a multi-decade entrepreneurial network across IT, cybersecurity, health, and infrastructure sectors.

Product overview

RAD BioMed Accelerator is the investment arm of the RAD Bynet Group, focusing on early-stage venture investing in Israel across Health, Technology, and Energy sectors. The portfolio comprises 14 distinct portfolio companies spanning MedTech, biotech, e-mobility, and related sectors. The portfolio includes vascular access solutions (Laminate, VGS), neurovascular treatments (Perflow), cardiac monitoring (Vectorious), stroke AI triage (CVAid Medical), mobility technology (SoftWheel, REE), women's health (FEMSelect), ophthalmology (Belkin Vision, Everads Therapy), radiation safety (Radiaction Medical), endoscopy (Zsquare), osteoarthritis treatment (Moebius Medical), and synthetic biology vaccines (Synvaccine). Several portfolio companies have achieved successful exits including Vectorious (acquired by Edwards Lifesciences for $497M in 2025), Belkin Vision (acquired by Alcon in 2024), Perflow (acquired by Chinese private equity), and REE (IPO).

Differentiator

Problem solved

Functional benefit

Products and services

• RAD BioMed Accelerator Program Early-stage venture accelerator program that provides equity investment plus hands-on company-building support (R&D, regulatory, clinical, operational, and strategic guidance) to Israel-based founding teams across MedTech, Health, Technology, and Energy sectors. Portfolio founders join a long-term entrepreneurial community backed by the four-decade RAD Bynet Group ecosystem.
• Early-Stage Equity Investment

Quantifiable outcome

• Vectorious acquired for $497 million by Edwards Lifesciences
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Nine partnerships are on record, tiered core and flagship.

• Square One LabscoreStrategic or Co-development Partner · 1 July 2024RAD Biomed partnered with Square One Labs to build and invest in deep tech technological companies in Energy and Physical AI sectors. This partnership expands RAD BioMed's focus beyond healthcare to include energy and AI-driven physical technology ventures.
• RAD Bynet GroupflagshipOthersRAD BioMed is the investment arm of the RAD Bynet Group, one of Israel's most successful tech ecosystems. The partnership provides RAD BioMed with access to four decades of company-building expertise, extensive entrepreneurial network, and proven track record of 17 companies, 9 IPOs, and 10 M&As.
• Tel Aviv UniversitycoreStrategic or Co-development PartnerSynvaccine's technologies are licensed exclusively from Tel Aviv University, enabling design-by-computer of viral genomes and DNA editing of viral vaccine genome libraries.
• Weizmann InstitutecoreStrategic or Co-development PartnerSynvaccine's disruptive technologies are licensed exclusively from the Weizmann Institute, enabling revolutionary cancer immunotherapies and vaccines.
• Sheba Medical Center at Tel HashomercoreStrategic or Co-development PartnerEverads Therapy's underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer, one of Israel's leading medical institutions.
• Hebrew UniversitycoreStrategic or Co-development PartnerMoebius Medical's patented technology is licensed from Hebrew University for developing novel pain relief treatments for osteoarthritis.
• TechnioncoreStrategic or Co-development PartnerMoebius Medical's patented technology is licensed from Technion for developing novel pain relief treatments.
• Hadassah Medical CentercoreStrategic or Co-development PartnerMoebius Medical's patented technology is licensed from Hadassah Medical Center for osteoarthritis treatment development.
• Sun Pharmaceutical IndustriesflagshipStrategic or Co-development PartnerIn 2016, Moebius Medical entered into an exclusive worldwide licensing deal with India's Sun Pharmaceutical Industries Ltd. to develop MM-II, a novel pharmaceutical candidate for osteoarthritis pain treatment.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• MindUP Digital Health Incubator: Israel-based digital health and medtech incubator, an initiative of the Israel Innovation Authority, operating with a similar accelerator model for early-stage health ventures.
• eHealth Ventures: Israel-based digital health incubator backed by hospitals, health systems, and corporate partners that builds early-stage healthcare ventures — comparable as a sector-focused accelerator with corporate backing.
• Trendlines Medical: Israeli medical device incubator and investment group that creates, invests in, and incubates early-stage medtech companies. Highly comparable to RAD BioMed in mandate, geography, and company-building model.
• Pontifax (Pontifax Global Healthcare): Israel-based healthcare-focused venture capital firm investing in life sciences and medical technology. Comparable as a healthcare-focused Israeli investor backing development-stage therapeutics and devices.
• aMoon Fund: Israeli venture capital firm focused on healthcare and life sciences, investing in biopharma, medtech, and digital health. Closely comparable mandate and geographic focus to RAD BioMed.
• Peregrine Ventures: Israeli venture capital firm focused on early-stage medical device and healthcare technology companies, with a hands-on company-building approach similar to RAD BioMed's accelerator model.
• MEDX Ventures Group: Israel-based medical device incubator and investment platform building early-stage healthcare companies — directly comparable in accelerator structure, medtech focus, and Israeli base.

Broad incumbents

• Johnson & Johnson Innovation (JLABS): Global corporate accelerator/incubator network providing lab space and company-building support for healthcare startups. Comparable as a corporate-backed accelerator model, but with broader geographic reach and bigger portfolio.
• Plug and Play Tech Center: Global corporate innovation platform and accelerator running health, biotech, and deep tech programs with corporate partners. Comparable as a multi-sector corporate accelerator but with much broader scale and corporate-partner model.

Emerging players

• MBC BioLabs: San Francisco-based biotech incubator providing lab space and company-building support to early-stage life sciences startups. Comparable as an early-stage life sciences incubator, but US-based and not focused on Israel.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Radbiomed1
• Facebookfacebook.com/RADBioMed

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RAD BioMed Accelerator